Contents
Company
Introduction
The best partner for precision medicine
History
Our company is continuing to grow as a global bio enterprise through more than two decades of built-up technological expertise and consistent innovation efforts
2023
- 2023.08
- Change in CEO, with Oh Su Yeon continuing as CEO
and Yang Sung woo as co-CEO
- 2023.06
- The largest shareholder of Crystal Genomics
- 2023.01
- Took over the pharmaceutical quality management business
2022
- 2022.11
- Change in CEO, with Shin Yong-gyu continuing as CEO
and Byeon Seok-su joining as co-CEO
- 2022.07
- Acquired Procagen, a Korean biopharmaceutical company
- 2022.06
- Establishment of Invites Genomics
- 2022.04
- Obtained CAP (College of American Pathologists) certification
2021
- 2021.04
- Change of name from BioCore Co., Ltd. to
Invites BioCore Co., Ltd.
- 2021.03
- COVID-19 diagnostic kit approved for domestic use
2020
- 2020.07
- Change of largest shareholder
from two individuals from Dian Diagnostics (Hong Kong)
Limited to two individuals from Invites Healthcare Co., Ltd.
- 2020.05
- Obtained FDA EUA approval for COVID-19 diagnostic kit
in the United States
- 2020.05
- Received emergency use authorization
from the Korea Centers for Disease Control and Prevention (KCDC) for COVID-19 diagnostic kit
2019
- 2019.04
- Received European CE certification for world's first
non-invasive trisomy screening (NITS)
2016
- 2016.04
- Approval for genetic diagnosis (MFDS & CDC)
2015
- 2015.09
- Took over the business of the Human Genome-Cell Genetic Business Department of the Seoul Medical Science Institute
- 2015.06
- Listed on KONEaX, becoming the first domestic clinical
CRO company to do so.
- 2015.03
- Attracted investments from China's Dian Group and domestic investment firms (KRW 12 billion).
2014
- 2014.12
- M&A with Ginocheck Co., Ltd.
(genome analysis, DNA chip manufacturer)
2012
- 2012.10
- Certified as a venture company -
Technology Guarantee Fund
- 2012.09
- InnoBiz (Innovative Small and Medium Business) certification - Small and Medium Business Administration
- 2012.09
- Established in-house research institute and awarded
2010
- 2010.05
- Started clinical trial CRO services (phase 1 and 2).
2008
- 2008.10
- Conducted the biological equivalence test and received certification from the MFDS, becoming the first institution to do so.
2005
- 2005.05
- Obtained GLP certification, the first in the field of
Bio-analytical CRO in Korea.
2001
- 2001.06
- Started offering the first biological equivalence testing service in Korea.
- 2001.05
- Established Biocore Co., Ltd.